Replies to post #156948 on Avid Bioservices Inc (CDMO)

[BioBS2012]

" Using multiple tumor models in mice, we demonstrate PS targeting antibodies enhance the anti-tumor activity of multiple forms of therapy including anti-CTLA-4 and anti-PD-1 checkpoint inhibitor antibodies."

Dia, when you look at the above quote and also the title of the presentation, it certainly looks like this will be the first disclosure of the PD-1 data with BAVI.

GTC Novel Immunotherapeutics Summit 2014- Jan 30
Speaker: Bruce Freimark, PhD, Phosphatidylserine Targeting Antibodies Enhances Activity of Immune Checkpoint Inhibitors and Re-activates Immune System in Tumors

Should be interesting in deed. I would even venture to say that we will see the data release via a PR prior to the presentation - maybe even next week? For sure during the week of January 27th. !!

[biopharm]

dia, you are correct. There is much to look forward to and its becoming clear that Peregrine should have some new combination data that just may further prove how well Bavituximab works with the likes of anti-PD-1 or CTLA-4..etc.

All I have to say is after reading this next article, I am hoping "Calico" has their contacts looking directly at Peregrine and ready to tear up Big Pharma.

Google contact lens could be option for diabetics

Jan 17, 2014

Brian Otis gingerly holds what looks like a typical contact lens on his index finger. Look closer. Sandwiched in this lens are two twinkling glitter-specks loaded with tens of thousands of miniaturized transistors. It’s ringed with a hair-thin antenna. Together these remarkable miniature electronics can monitor glucose levels in tears of diabetics and then wirelessly transmit them to a handheld device.

‘‘It doesn’t look like much, but it was a crazy amount of work to get everything so very small,’’ he said before the project was unveiled Thursday.

During years of soldering hair-thin wires to miniaturize electronics, Otis burned his fingertips so often that he can no longer feel the tiny chips he made from scratch in Google’s Silicon Valley headquarters, a small price to pay for what he says is the smallest wireless glucose sensor ever made.

http://www.boston.com/business/technology/2014/01/17/google-contact-lens-could-option-for-diabetics/IdiVMEyoKqHLUAQSWgqnOL/singlepage.html

[Protector]

More importantly: PD-1 is NOT FDA approved as was CTLA-4.

That means PPHM could not do any pre-clinical or clinical trial with PD-1 without the authorisation of the BP that owns it (Merck I think or was it Roche).

That means they've talked about it!